{"id":"NCT02159053","sponsor":"Novartis Pharmaceuticals","briefTitle":"16-week Efficacy and 2-year Safety, Tolerability and Efficacy of Secukinumab in Participants With Active Ankylosing Spondylitis","officialTitle":"A Randomized, Double-blind, Placebo-controlled, Phase III Multicenter Study of Subcutaneous Secukinumab (150 mg) With and Without a Subcutaneous Loading Regimen to Assess Efficacy, Safety, and Tolerability up to 2 Years in Patients With Active Ankylosing Spondylitis","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2015-05-18","primaryCompletion":"2016-02-23","completion":"2018-01-02","firstPosted":"2014-06-09","resultsPosted":"2019-04-10","lastUpdate":"2019-04-10"},"enrollment":350,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Spondylitis, Ankylosing"],"interventions":[{"type":"BIOLOGICAL","name":"Secukinumab","otherNames":["Secukinumab (AIN457) 150 mg s.c."]},{"type":"BIOLOGICAL","name":"Secukinumab","otherNames":["Secukinumab (AIN457) 150 mg s.c."]},{"type":"BIOLOGICAL","name":"Placebo","otherNames":[]}],"arms":[{"label":"Secukinumab 150 mg s.c. with loading","type":"EXPERIMENTAL"},{"label":"Secukinumab 150 mg s.c. without loading","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of this study is to provide 16-week efficacy, safety and tolerability data versus placebo to support the use of secukinumab 150 mg by subcutaneous (s.c.) self-administration with or without a loading regimen and maintenance dosing using pre-filled syringe (PFS) and to assess efficacy, safety and tolerability up to 2 years in subjects with active AS despite current or previous NSAID, non-biologic DMARD, or biologic anti-TNFÎ± therapy.","primaryOutcome":{"measure":"Percentage of Participants Responded for Assessment of Spondyloarthritis International Society 20 Criteria (ASAS20) at 16 Weeks","timeFrame":"16 Weeks","effectByArm":[{"arm":"Secukinumab 150 mg With Loading Dose","deltaMin":60.5,"sd":null},{"arm":"Secukinumab 150 mg Without Loading Dose","deltaMin":65.5,"sd":null},{"arm":"Placebo","deltaMin":49.1,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":90,"countries":["United States","Australia","Austria","Bulgaria","Canada","Czechia","Denmark","Finland","Germany","Greece","Italy","Netherlands","Norway","Poland","Russia","Slovakia","Spain","Switzerland","United Kingdom"]},"refs":{"pmids":["35305260","34773130","34618347","33722947","31203228","30121827"],"seeAlso":["http://www.novartisclinicaltrials.com"]},"adverseEventsSummary":{"seriousAny":{"events":18,"n":116},"commonTop":["Nasopharyngitis","Upper respiratory tract infection","Ankylosing spondylitis","Diarrhoea","Bronchitis"]}}